National Institute for Health and Care Excellence

TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis

The Assessment Group conducted a systematic review and identified 24 relevant randomised controlled trials (RCTs): 19 recruited people with ankylosing spondylitis, 4 recruited people with axial ...
Nature

Disease modification in ankylosing spondylitis

The concept of disease modification in ankylosing spondylitis (AS) incorporates aspects of inflammation, bone destruction and new bone formation. The degree to which inflammation and new bone ...
Medscape

Ankylosing Spondylitis: Prolonged Anti-TNF Stops Damage

(UPDATED July 25, 2013) — A major observational study in ankylosing spondylitis (AS) published online July 1 in Arthritis & Rheumatism revealed that tumor necrosis factor (TNF) inhibitors ...
Monthly Prescribing Reference

Data Support Upadacitinib in Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis

No new safety risks were identified in the studies. Positive topline results were announced from the phase 3 SELECT-AXIS 2 study evaluating upadacitinib in adults with active ankylosing spondylitis ...
Medscape

Smoking Accelerates Ankylosing Spondylitis Damage

ROME — In patients with ankylosing spondylitis, smoking might interact with epigenetic factors and promote radiographic progression, according to the first study of its kind. In an investigation of ...
Healio

Ankylosing spondylitis, non-radiographic axial spondyloarthritis carry similar disease burden

Please provide your email address to receive an email when new articles are posted on . Patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis share comparable disease burden ...
The American Journal of Managed Care

Bimekizumab Shows Long-Term Efficacy in Nonradiographic AxSpA, Ankylosing Spondylitis

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). Bimekizumab is currently FDA approved ...
Healio

Epigenetic factors may affect radiographic progression in ankylosing spondylitis

Please provide your email address to receive an email when new articles are posted on . Smoking and multiple epigenetic variables were found to be associated with radiographic progression in patients ...
Nasdaq

Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada announced today that Health Canada approved TALTZ® (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ...
Science Daily

Mechanism regulating gene expression linked to bone and joint damage in ankylosing spondylitis

A new study reveals that DNA methylation -- a mechanism that regulates gene expression -- could influence the progression of structural damage to the joints and spine in ankylosing spondylitis. Study ...
National Institute for Health and Care Excellence

TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis

Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233): assessment report Ankylosing spondylitis and axial ...